Pritor^®/Kinzalmono^® is indicated for the treatment of essential hypertension and for the reduction of cardiovascular morbidity in patients with:

• I. Manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or
• II. Type 2 diabetes mellitus with documented target organ damage

PritorPlus^®/Kinzalkomb^® is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.